Jeito Capital II's €1B European Biopharma Fund: LPs Back EU Healthcare at Scale
Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.
Venture Capital News, Guides & Fund Directory
Venture capital fuels the companies that reshape industries — from AI infrastructure and fintech to healthcare and defense tech. This hub collects our latest analysis on how VC firms evaluate startups, structure deals, and deploy capital across stages and geographies.
What You'll Find Here
- Fund profiles & directories: Stage focus, sector thesis, and check-size context for active investors
- Deal flow analysis: Funding roundups, mega-rounds, and emerging-manager activity
- Founder playbooks: Pitch decks, term sheets, warm intros, and fundraising strategy
- Market intelligence: Sector trends, valuation shifts, and LP allocation patterns
Browse the articles below to research investors, understand deal dynamics, and build a sharper fundraising strategy.
Related Articles (594 articles)
-
-
Blackstone's $10B Capital Opportunities V: Private Credit Reshapes the VC Exit Path
Blackstone's opportunistic private credit fund is not VC, but its scale directly changes how venture-backed companies refinance, recapitalize, and exit.
-
KKR's $23B North America PE Fund: Scale Capital Reshapes the Growth-Stage VC Market
Mega buyout funds like KKR's 2026 vehicle aren't traditional VC, but they materially influence late-stage startup exits and crossover rounds.
-
Alcatraz's $50M Series B: Physical Security Is Being Rebuilt for the AI Infrastructure Era
Alcatraz's April 2026 round reflects growing demand for privacy-aware biometric access systems in critical facilities.
-
April 2026 NYC + U.S. VC Funding Roundup: Deals, Tables, and Q2 Signals
April 2026 VC funding roundup with NYC and U.S. deal tables — what raised, at what stage, and what founders should do next. Links to the live fund tracker.
-
Avo's $10M Series A: Clinical AI Is Moving Closer to Point-of-Care Decisions
Avo's April 2026 Series A highlights investor demand for AI systems that integrate directly into clinical workflows.